Navigation Links
MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:3/4/2008

nutes early to register, download, and install any necessary audio software. The call will also be archived on the MiddleBrook website.

About MiddleBrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on the development and commercialization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front- loaded staccato bursts, or "pulses," are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(R). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) - the first and only once-daily amoxicillin product approved for marketing in the U.S. For more on MiddleBrook, please visit http://www.middlebrookpharma.com.

About MOXATAG:

MOXATAG(TM) (amoxicillin extended-release) tablets are a once-a-day extended-release formulation of amoxicillin for oral administration consisting of three components: one immediate-release and two delayed-release. The three components are combined in a specific ratio to prolong the release of amoxicillin from MOXATAG compared to immediate-release amoxicillin. MOXATAG is intended to provide a lower treatment dose, once-daily alternative to currently approved penicillin and amoxicillin regimens for the treatment of adults and pediatric patients 12 years and older with tonsillitis and/or pharyn
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2009)...tCall/ - avVaa World Health Care Products Inc. (Pi...manufacturer and distributor of nationally branded...s, announced the engagement of Koeppel Direct to m... Campbell-Farley, President/COO of avVaa World Hea...Direct, a world-class direct response television m...
(Date:7/1/2009)...ue that identifies and removes systematic bias, no...l data could lead to more precise and reliable mea...y to have future industrial applications. , Know...SPAR), the technique could also reduce the amount ... and help distinguish true nanoscale phenomena fro...
(Date:7/1/2009)... Johnson & Johnson today announced that Axel U...ular Biology at the Max Planck Institute of Bioche...ovel cancer therapies including Herceptin(R) (tras...sen Award for Biomedical Research. An independent .... Ullrich, who on September 8 will receive a $100,...
(Date:7/1/2009)...establish duration of efficacy from two hours up t...D , , HOLLYWOOD, Fla., July 1 /PRNewswire-First...he global specialty biopharmaceutical company, tod...und VYVANSE(R) (lisdexamfetamine dimesylate) CII d... administration during a simulated workplace envir...
Breaking Biology Technology:avVaa World Health Care Products, Inc. Announces Engagement of Koeppel Direct for their DRTV-Direct Response Television Media Buying Campaign 2New statistical technique improves precision of nanotechnology data 2New statistical technique improves precision of nanotechnology data 3New statistical technique improves precision of nanotechnology data 4Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 2Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 3Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 4Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 5Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 2Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 3Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 4Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 5Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 6Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 7Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 8
...n Bay, Wis. - The Green Bay Fire Department has...002 as a database to keep and manage its records. ...e department recently awarded BIO-key Internation...f , an automatic scheduling system from Principal...ogram seemed a natural choice for the department. ...
...son, Wis. - The Proceedings of the National Acad...rs at the University of Wisconsin-Madison and Co... of the genetic disorder Huntington,s disease. , ,...dison molecular geneticist Jerry Yin and UW-Madiso...vating levels of the proteins CREB and HSP-70 in ...
...son, Wis. - When Hurricane Dennis reached landfal... too surprising a development. Weather Central In... solutions had already forecast almost the exact l...ather Central,s Super MicroCast forecast model, a ...throughout the country, showed Hurricane Dennis ma...
...son, Wis. - R&D Magazine has selected Bruker A... Award, which recognizes the most technologically ...ce during the past year. , ,The VANTEC-2000 system...logy useful in the life science, materials science...ers to determine small molecule and protein struct...
Other Biology Technology:IT application streamlines fire fighting 2IT application streamlines fire fighting 3
(Date:7/2/2009)... pathology and laboratory medicine at The Universi...received a Career Development Award from the Natio...port Smith,s research into the development of a th...order, whose immune systems are resistant to treat...0 males born in the United States. , Through the...
(Date:7/2/2009)...es its birth on the 4th of July, University of Mia...n coral reef nursery scientists will be celebratin...dministration (NOAA) today announced that The Natu...orn coral recovery project, including Lirman,s nur...rt from the American Recovery and Reinvestment Act...
(Date:7/1/2009)...y announced that Axel Ullrich, Ph.D., director of ...nck Institute of Biochemistry in Germany, whose di...ding Herceptin (trastuzumab) , is the winner of th...rch. An independent committee of world-renowned s... will receive a $100,000 prize during a ceremony i...
(Date:7/1/2009)... centromere, a key cellular structure in powering ...e cell division, has just earned him a paper in N...ation grant, of 50,000 euro per year, for a maximu...rnia to the Instituto Gulbenkian de Cincia (IGC), ...anisms group. The Nature Cell Biology paper, pub...
Breaking Biology News(10 mins):UT scientist receives hemophilia research award 2Nursery programs for corals receive TLC from NOAA this Independence Day 2Axel Ullrich named winner of 2009 Dr. Paul Janssen Award for Biomedical Research 2Double success for Instituto Gulbenkian de Ciencia scientists working on chromosome segregation 2Controversies in science and technology explored in new book from Mary Ann Liebert 12286 1Controversies in science and technology explored in new book from Mary Ann Liebert 12286 2XTENT Announces 2007 Financial Results 12282 1XTENT Announces 2007 Financial Results 12282 2XTENT Announces 2007 Financial Results 12282 3XTENT Announces 2007 Financial Results 12282 4XTENT Announces 2007 Financial Results 12282 5XTENT Announces 2007 Financial Results 12282 6No Difference Found in Treatments for Acute Kidney Failure 12280 1No Difference Found in Treatments for Acute Kidney Failure 12280 2No Difference Found in Treatments for Acute Kidney Failure 12280 3Peacetime use of radioisotopes at Oak Ridge cited as Chemical Landmark 12276 1Peacetime use of radioisotopes at Oak Ridge cited as Chemical Landmark 12276 2Peacetime use of radioisotopes at Oak Ridge cited as Chemical Landmark 12276 3
...rvard University and University College London hav...socially disabling inability to recognize or disti...d a related web site ( www.faceblind.org ) to iden...e than scientists had identified previously. , Th...sell at Harvard and Bradley Duchaine at University...
...sed data from scans of 183 subjects to identify br...iety of cognitive tasks, such as reading, learning...n action can be compared to a symphony, with speci...time to produce the desired melody, then the regio...conductors, researchers at Washington University S...
...ious diseases run in families because one inherits...rally agree that an individual,s genetic makeup co...ctious disease, new findings from researchers in F... in a single gene is enough to dramatically alter ...ns. , Howard Hughes Medical Institute (HHMI) in...
...do not haphazardly flail about looking for a host ...nts and identify potential hosts by their emission...ogists. , "We are interested in how plants respond...sect interactions," says Dr. Consuelo M. De Moraes...rising to see how little was available on how abov...
Other Biology News:Tests for 'face-blindness' reveal disorder may not be so rare 2Master planners in brain may coordinate other areas' roles in cognitive tasks 2Master planners in brain may coordinate other areas' roles in cognitive tasks 3Inheriting a tendency to brain infection 2Inheriting a tendency to brain infection 3Parasitic plants sniff out hosts 2Parasitic plants sniff out hosts 3
Defender against cell death 1
Wnt-1 (G-19)
Mouse monoclonal [TONI-1] to Angiotensin II Type 1 Receptor (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 185 SwissProtID: P30556
G4-1, Affinity-Purified Polyclonal IgY Antibodies Hypothetical protein FLJ20644, likely ortholog of mouse phosphatase subunit gene g4-1 Protein Accession #: NP_060387.1 gi number query: 8923600
Biology Products: